GlassScriptPhysician profile
Scott Schlachter
NPI 1346213386
$6,542.95
in general payments reported to CMS, 2019-2025
33 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $922 · 2021: $1,235 · 2022: $578 · 2023: $748 · 2024: $959 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,840 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00 · Education: $15.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,839.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
| Education | $15.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,691.53 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Abbvie INC. | $1,249.48 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $940.76 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $440.35 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $289.68 | 2019-2024 | Entyvio, Gattex |
| Gilead Sciences, INC. | $279.29 | 2019-2023 | |
| Qol Medical, LLC | $234.90 | 2019-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $154.24 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $153.60 | 2025 | Terlivaz |
| Ferring Pharmaceuticals INC. | $152.74 | 2019-2023 | Cimzia |
| Genzyme Corporation | $125.08 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $109.00 | 2024 | Tremfya |
| Ironwood Pharmaceuticals, INC | $93.97 | 2019-2021 | |
| Celgene Corporation | $87.13 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $69.28 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $64.64 | 2020 | |
| Nestle Healthcare Nutrition INC. | $59.86 | 2021-2023 | |
| Evoke Pharma, INC. | $56.61 | 2021-2025 | |
| Daiichi Sankyo INC. | $51.95 | 2020-2022 | |
| Lilly USA, LLC | $37.85 | 2024 | Omvoh |
| Shire North American Group INC | $24.65 | 2019 | |
| Novo Nordisk INC | $18.52 | 2025 | Wegovy |
| Romark Laboratories, Lc | $17.14 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.46 | 2024 | Cyltezo |
| Celltrion USA INC. | $15.01 | 2024 | Zymfentra |
| Ucb, INC. | $14.83 | 2019 | |
| Medtronic, INC. | $14.58 | 2021 | |
| Medtronic USA, INC. | $14.31 | 2019 | |
| Redhill Biopharma INC. | $14.17 | 2020 | |
| Ardelyx, INC. | $13.57 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $13.46 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $12.68 | 2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $12.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Schlachter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.